Defining the cellular and molecular pathogenesis of ulcerative colitis
Defining the cellular and molecular pathogenesis of ulcerative colitis
批准号:
G0802068/1
负责人:
Graham Lord
金额:
$149.41万
依托单位:
依托单位国家:
英国
项目类别:
Research Grant
财政年份:
2009
资助国家:
英国
项目状态:
已结题
起止时间:
2009 至 --
中文摘要
溃疡性结肠炎(UC)是一种无法治愈的肠道疾病,可以影响所有年龄段的男性、女性和儿童。它会导致严重的腹痛、带血腹泻,甚至癌症,许多患者需要手术来缓解这些症状和并发症。尤其令人担忧的是,这种情况变得越来越普遍,没有人真正知道是什么导致了这种情况,也没有人知道最好的治疗方法是什么。这项研究旨在了解更多导致UC的原因,并可能导致新疗法的发展。我们最近的工作让我们对加州大学可能发生的事情有了很好的了解。我们发现免疫系统细胞中的一种特殊基因可以破坏“好”与“坏”之间的平衡。和坏?肠道内的细菌会引发肠道炎症。研究表明,这种基因(被称为T-bet)控制着一种叫做tnf - α的关键蛋白质的产生。没有T-bet,就会产生过多的这种蛋白质,从而引发肠道炎症。这反过来又使细菌从肠道进入体内,从而加重炎症并引起溃疡性结肠炎。我们的工作是揭示“好”与“坏”之间的关键平衡。和坏?细菌维持在肠道中,当肠道紊乱时,什么会出问题。UC是一种?自身免疫性疾病?那发生在什么时候?人体的免疫系统犯了一个错误并攻击自己。这可能是由阻止免疫细胞攻击肠道细菌的细胞屏障破裂引起的。我们吗?我们已经发现T-bet基因对于维持屏障的完整性至关重要。它吗?就像我们的内脏里有一个维和人员,没有它,事情会变得很糟糕。更多地了解导致溃疡性结肠炎的事件,为治疗它开辟了几种可能的新方法。除了开发影响T-bet的药物外,另一种方法可能是使用特殊的?调节性免疫细胞?这种药物已被证明对治疗小鼠溃疡性结肠炎有效。这些结果非常重要,我们希望以更详细的方式研究这些小鼠,以发现治疗这种疾病的新方法,例如恢复一些调节性T细胞。我们的目标是将实验室的这些发现转化为新的治疗方法,以尽快帮助患者。
英文摘要
Ulcerative colitis (UC) is an incurable disease of the guts which can affect men, women and children of all ages. It can cause severe abdominal pain, bloody diarrhoea, and even cancer and many patients require surgery to help with these symptoms and complications. What is particularly worrying is that this condition is becoming more common and nobody really knows what causes it or what the best treatment is.This research aims to understand more about what causes UC and may lead to the development of new therapies.Our recent work has given us great insight in to what is likely to be going on in UC. We have found that one particular gene in cells of the immune system can upset the balance between ?good? and ?bad? bacteria in the gut and trigger inflammation in the bowel. The research showed that this gene (known as T-bet) controls the production of a key protein called TNF-alpha. Without T-bet, too much of this protein gets produced, which starts the process of inflammation in the gut. This in turn allows bacteria to cross from the gut into the body, which can aggravate the inflammation and cause ulcerative colitis. Our work is uncovering the ways in which the crucial balance between ?good? and ?bad? bacteria is maintained in the gut and what goes wrong when it is upset.UC is one type of ?autoimmune disease? that occurs when the body?s immune system makes a mistake and attacks itself. This can be triggered by the breakdown of the barrier of cells that prevents immune cells from attacking bacteria in the bowel. We?ve found that the T-bet gene is essential for maintaining the integrity of that barrier ? it?s like a peacekeeper in our guts and without it, things can get nasty.Knowing more about the events that lead to ulcerative colitis opens up several possible new ways to treat it. As well as developing drugs that affect T-bet, another approach might be to use special ?regulatory immune cells?, which have already proved effective at treating ulcerative colitis in mice.These results are very important and we hope to study these mice in a more detailed way to discover new treatments for patients with this disease, such as giving back some regulatory T cells.We aim to take these findings from the lab and turn them into new treatments to help patients as quickly as possible.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
MICA: Targeted Regulatory T Cell Therapy for Inflammatory Bowel Disease
-
批准号:MR/N006445/1
-
项目类别:Research Grant
-
资助金额:$423.08万
-
财政年份:2016
-
负责人:Graham Lord
-
依托单位:
T-bet as a master regulator of mucosal immunity and inflammatory bowel disease.
-
批准号:MR/M003493/1
-
项目类别:Research Grant
-
资助金额:$158.64万
-
财政年份:2015
-
负责人:Graham Lord
-
依托单位:
Redistribution of Gata3 by T-bet: a novel mechanism underlying T-cell lineage balance
-
批准号:BB/L010356/1
-
项目类别:Research Grant
-
资助金额:$16.91万
-
财政年份:2014
-
负责人:Graham Lord
-
依托单位:
Consortium Building
-
批准号:MR/K500999/1
-
项目类别:Research Grant
-
资助金额:$2.55万
-
财政年份:2013
-
负责人:Graham Lord
-
依托单位:
国内基金
海外基金
登录
查看更多内容
基于MFSD2A调控血迷路屏障跨细胞囊泡转运机制的噪声性听力损失防治研究
-
批准号:82371144
-
项目类别:面上项目
-
资助金额:49.00万元
-
批准年份:2023
-
负责人:汪雪玲
-
依托单位:
长寿基因SIRT7调控核苷酸切除修复通路的机制研究
-
批准号:32100605
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:耿安珂
-
依托单位:
溶酶体蛋白LAPTM4B通过与Xc-系统相互作用调控谷胱甘肽代谢的机制研究
-
批准号:32100623
-
项目类别:青年科学基金项目(C类)
-
资助金额:30.0万元
-
批准年份:2021
-
负责人:周可成
-
依托单位:
小鼠肺分支早期发育中肺上皮单细胞的时-空转录组的建立与分析
-
批准号:32070795
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:蔡军
-
依托单位:
乳腺癌上皮间质转化中核苷酸代谢相关的功能蛋白发现和机理研究
-
批准号:32070748
-
项目类别:面上项目
-
资助金额:54.0万元
-
批准年份:2020
-
负责人:戴凌云
-
依托单位:
rhTβ4增强间充质干细胞调节T细胞代谢重塑治疗干眼的机制研究
-
批准号:32000530
-
项目类别:青年科学基金项目
-
资助金额:24.0万元
-
批准年份:2020
-
负责人:陈小鸟
-
依托单位:
胰岛素和细菌信号协同调节巨噬细胞免疫反应的作用
-
批准号:92057105
-
项目类别:重大研究计划
-
资助金额:89.0万元
-
批准年份:2020
-
负责人:Tiffany Shy Yea Horng
-
依托单位:
胞浆甘氨酰-tRNA合成酶cytoGARS感知甘氨酸的分子机制及其对肝细胞癌的影响
-
批准号:32070756
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2020
-
负责人:汪维
-
依托单位:
葡萄糖调节的AXIN溶酶体膜转运的分子机制
-
批准号:32070753
-
项目类别:面上项目
-
资助金额:59.0万元
-
批准年份:2020
-
负责人:李梦琪
-
依托单位:
一种全新的高尔基体胆固醇感应蛋白的鉴定和功能研究
-
批准号:32070755
-
项目类别:面上项目
-
资助金额:58.0万元
-
批准年份:2020
-
负责人:钟辉
-
依托单位: